Sinovac climbs on 1Q hepatitis A vaccine sales
Sinovac rises after saying 1st-quarter hepatitis A vaccine sales more than tripled
NEW YORK (AP) -- Shares of Sinovac Biotech Ltd. jumped Tuesday after the Chinese vaccine maker reported a smaller first-quarter loss and stronger sales of its hepatitis A vaccine Healive.
Sinovac said sales of Healive climbed to $6.2 million from $1.6 million a year ago. That made up for lower sales of Bilive, a combination hepatitis A and B vaccine. The company also posted $585,000 in sales of a new mumps vaccine.
Sinovac took a loss of $1.8 million, or 4 cents per share. A year ago, it reported a loss of $5 million, or 10 cents per share. Revenue grew to $10.1 million from $6 million.
The company said Bilive sales fell to $3 million from $4 million. Influenza vaccine sales slipped to $294,000 from $314,000 and revenue from animal vaccines decreased to $13,000 from $32,000.
U.S.-traded shares of Sinovac rose 66 cents, or 19.9 percent, to $3.97 in Tuesday afternoon trading.
